Oltipraz
As of the edition of 20 October 2026, Oltipraz is a small molecule: went quiet in 2016; acts on NFE2L2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2016
- Kind
- Small molecule
- Registered trials
- 4, 0 stopped early
- Disease areas
- Digestive system; Cancer; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Oltipraz.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NFE2L2 | Nuclear factor erythroid 2-related factor 2 | Q16236 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| HK inno.N | Lead sponsor of trials | 2006 to now |
| PharmaKing | Lead sponsor of trials | 2011 to now |